University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Drug Saf. 2023 Jul;46(7):677-687. doi: 10.1007/s40264-023-01312-5. Epub 2023 May 24.
Nephrotoxin exposure is significantly associated with acute kidney injury (AKI) development. A standardized list of nephrotoxic medications to surveil and their perceived nephrotoxic potential (NxP) does not exist for non-critically ill patients.
This study generated consensus on the nephrotoxic effect of 195 medications used in the non-intensive care setting.
Potentially nephrotoxic medications were identified through a comprehensive literature search, and 29 participants with nephrology or pharmacist expertise were identified. The primary outcome was NxP by consensus. Participants rated each drug on a scale of 0-3 (not nephrotoxic to definite nephrotoxicity). Group consensus was met if ≥ 75% of responses were one single rating or a combination of two consecutive ratings. If ≥ 50% of responses indicated "unknown" or not used in the non-intensive care setting, the medication was removed for consideration. Medications not meeting consensus for a given round were included in the subsequent round(s).
A total of 191 medications were identified in the literature, with 4 medications added after the first round from participants' recommendations. NxP index rating consensus after three rounds was: 14 (7.2%) no NxP in almost all situations (rating 0); 62 (31.8%) unlikely/possibly nephrotoxic (rating 0.5); 21 (10.8%) possibly nephrotoxic (rating 1); 49 (25.1%) possibly/probably nephrotoxic (rating 1.5); 2 (1.0%) probably nephrotoxic (rating 2); 8 (4.1%) probably/definite nephrotoxic (rating 2.5); 0 (0.0%) definitely nephrotoxic (rating 3); and 39 (20.0%) medications were removed from consideration.
NxP index rating provides clinical consensus on perceived nephrotoxic medications in the non-intensive care setting and homogeneity for future clinical evaluations and research.
肾毒物暴露与急性肾损伤(AKI)的发展显著相关。对于非危重症患者,目前尚不存在需要监测的肾毒性药物的标准化清单,以及这些药物的潜在肾毒性(NxP)。
本研究旨在就非重症监护环境中使用的 195 种药物的肾毒性作用达成共识。
通过全面的文献检索确定潜在的肾毒性药物,然后确定了 29 名具有肾病学或药剂学专业知识的参与者。主要结局是通过共识确定 NxP。参与者对每种药物进行评分,分值为 0-3 分(无肾毒性到明确的肾毒性)。如果≥75%的应答为单一评分或两个连续评分的组合,则达到组共识。如果≥50%的应答表示“未知”或未在非重症监护环境中使用,则将该药物排除在考虑之外。对于某一轮未达成共识的药物,将其纳入后续轮次(如果有)。
文献中总共确定了 191 种药物,第一轮后根据参与者的建议又增加了 4 种药物。三轮后 NxP 指数评分共识结果为:14(7.2%)在几乎所有情况下均无 NxP(评分 0);62(31.8%)不太可能/可能肾毒性(评分 0.5);21(10.8%)可能肾毒性(评分 1);49(25.1%)可能/很可能肾毒性(评分 1.5);2(1.0%)很可能/肯定肾毒性(评分 2);8(4.1%)很可能/肯定肾毒性(评分 2.5);0(0.0%)肯定肾毒性(评分 3);39 种(20.0%)药物被排除在考虑之外。
NxP 指数评分提供了非重症监护环境中潜在肾毒性药物的临床共识,以及未来临床评估和研究的同质性。